Key result
China sees a ~74% drop in age-standardized PAH mortality from 1990 to 2023.
Why the study?
Pulmonary arterial hypertension causes substantial premature mortality and disability, but updated evidence comparing long-term disease burden in China with the G20 aggregate remains limited.
Observational
Effect estimate: AAPC -3.96% (95% CI -4.42 to -3.49)
Absolute Event Rate: 0.08% vs 0.29%
While age-standardized mortality from PAH has significantly declined in China and the G20 aggregate over the past three decades, the absolute number of prevalent cases continues to rise due to population growth and aging.
Declining PAH mortality rates in China may expand caseloads amid aging; leaves open optimal strategies for rising prevalent cases.
BACKGROUND: Pulmonary arterial hypertension (PAH) causes substantial premature mortality and disability. Updated evidence comparing long-term PAH burden in China with the Group of Twenty (G20) aggregate remains limited. We assessed changes from 1990 to 2023 and projected future trends. METHODS: PAH estimates for China and the G20 aggregate were extracted from the Global Burden of Disease Study 2023. Outcomes included incidence, prevalence, deaths, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs), expressed as absolute counts and age-standardized rates. Temporal trends were assessed using Joinpoint regression. Sex-specific and age-specific patterns and demographic decomposition were examined. Autoregressive integrated moving average (ARIMA) models projected overall burden through 2050. Bayesian age-period-cohort (BAPC) models projected sex-specific patterns through 2038. RESULTS: From 1990 to 2023, incident and prevalent cases and YLDs increased in both settings, whereas deaths, DALYs, and YLLs declined. In China, prevalent cases increased by 63.5%, from 17,020.87 to 27,834.41, while the age-standardized death rate decreased by 74.3%, from 0.29 to 0.08 per 100,000 population. Similar declines in mortality-related age-standardized indicators occurred in the G20 aggregate. Females generally had higher age-standardized prevalence and YLD rates than males, although sex differences in mortality-related outcomes varied by setting. Absolute burden shifted toward older age groups. Population growth and aging contributed to increases in absolute burden, whereas epidemiological change generally acted in the opposite direction. Projections suggested continued declines in age-standardized mortality-related burden through 2050, alongside increases in incident and prevalent case numbers. CONCLUSION: Mortality-related PAH burden declined in China and the G20 aggregate, while absolute case numbers increased. Population growth and aging contributed to this divergence, underscoring the need for continued surveillance and long-term health-service planning.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted an observational in Pulmonary arterial hypertension. Time period (1990 to 2023) vs. 1990 baseline was evaluated on Age-standardized death rate in China (per 100,000 population) (AAPC -3.96%, 95% CI -4.42 to -3.49). From 1990 to 2023, the age-standardized death rate for pulmonary arterial hypertension in China decreased by 74.3%, while absolute prevalent cases increased by 63.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: